Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] - N0000175623

Pharmacologic Class Information

Pharmacologic Code N0000175623
Pharmacologic Name Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Pharmacologic Uses
  • RSV anti-F protein monoclonal (mAb)
Pharmacologic Concept Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions:
  • A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication.
  • A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

NDC Products with Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody

The following table contains 2 products whose active ingredient are classified under the same pharmacologic class Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
66658-230Synagis Non-Proprietary Name: PalivizumabInjection, SolutionIntramuscularSwedish Orphan Biovitrum Ab (publ)ACTIVE
66658-231Synagis Non-Proprietary Name: PalivizumabInjection, SolutionIntramuscularSwedish Orphan Biovitrum Ab (publ)ACTIVE